Eli Lilly, Pfizer land on China’s first private insurance list
December 7, 2025 at 4:04 AM UTC
Updated on
December 8, 2025 at 2:40 AM UTC
Eli Lilly & Co., Pfizer Inc. and Johnson & Johnson secured spots on China’s first innovative drug catalog, opening a new market channel and boosting sales prospects for costly, cutting-edge treatments.
In all, 19 medicines made the list — a formulary of drugs deemed too expensive for state insurance but recommended for commercial health coverage — officials said in Guangzhou on Sunday. The drugs are for a range of conditions including cancer and Alzheimer’s, as well as rare genetic disorders.
Information contained on this page is provided by an independent third-party content provider. This website make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @producerpress.com
